Evidence of meeting #37 for Health in the 45th Parliament, 1st session. (The original version is on Parliament’s site, as are the minutes.) The winning word was industry.

A video is available from Parliament.

On the agenda

Members speaking

Before the committee

Godard  Director General, Natural and Non-Prescription Health Products Directorate, Department of Health
O'Connor  Director General, Health Product Compliance Directorate, Department of Health

The Chair Liberal Sukh Dhaliwal

I call the meeting back to order.

We will now continue with our second panel of witnesses. I would like to welcome the senior officials from the Department of Health. With us, we have the director general, health product compliance directorate, Ms. Sara O'Connor. Welcome. We also have the director general, natural and non-prescription health products directorate, Ms. Kim Godard.

Both of you are welcome, and you have five minutes to speak. Please go ahead. The floor is yours.

Kim Godard Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Thank you, Mr. Chair and members of the committee, for the opportunity to appear before you today. Health Canada welcomes the opportunity to participate in the study of Bill C‑224 to provide context on Canada's regulatory framework for natural health products, or NHPs.

Canada's NHP sector is vibrant and innovative, contributing over $13 billion annually to the Canadian economy. It includes a broad range of participants, from small, Canadian-owned retailers to manufacturers, distributors and importers, many of which operate internationally.

Health Canada is committed to ensuring that NHPs available to Canadians are safe and effective, and of high quality. We play a critical role in protecting Canadians by regulating products used daily to improve and maintain health, including probiotics, herbal remedies, vitamins and minerals, homeopathic medicines, traditional medicines, and other products such as amino acids and essential fatty acids.

While natural health products are often perceived as lower risk, they are not without risk and require measured oversight. From experience, we know that harm may arise from undeclared ingredients, contaminants, inaccurate labelling, inappropriate use or interactions with other health products, such as pharmaceuticals. Where risks are identified, our objective is to act proportionally and consistently to protect Canadians.

Canada is an international leader in NHP regulations. We are among the few that regulate these products as health products rather than food supplements. That allows NHPs to make health claims, which uniquely enhances their appeal in both domestic and international markets. This approach appropriately reflects their lower risk profile while recognizing their health benefits.

Health Canada's role is to regulate activities such as the sale, manufacturing, packaging, labelling and importing of NHPs across the spectrum of the market to ensure the products Canadians buy are safe, effective and of high quality.

The recognition that NHPs are distinct from other drugs is central to Bill C-224. It is a principle shared by Health Canada. The bill seeks to amend legislation passed in 2023 that extends postmarket authorities to NHPs by including them in the definition of therapeutic products. The 2023 legislative change did not replace the NHP framework with a prescription drug regime. Rather, it conferred on the Minister of Health new postmarket authorities, known as Vanessa's Law authorities, with respect to NHPs. These postmarket authorities enable Health Canada to take swift action when an NHP presents a serious risk to health, which is consistent with other products we regulate. This includes the ability to order recalls and to ensure courts can impose deterrents comparable to those in the Criminal Code.

At this pivotal moment, the government is focused on supporting Canadian business, including reducing unnecessary regulatory burden. In support of this objective, Health Canada is advancing a plan for a simplified registration process for certain NHPs, more flexible labelling and reduced premarket requirements where postmarket oversight is better suited.

The committee should be aware that several of the authorities introduced in 2023 also support the reduction of regulatory red tape. This includes the ability to incorporate documents by reference, which will support the proposed registration scheme and enable flexibilities around digital labelling. It also includes the authority to grant targeted exemptions. One example is the exemption order issued by the Minister of Health in 2025, which extended the compliance timelines for new NHP labelling requirements. This measure is widely supported by natural product stakeholders and provides important flexibility for industry and time to work with Health Canada to address implementation challenges while continuing to support consumer safety.

In closing, effective regulatory tools protect consumers by helping to ensure health products remain safe, and support businesses by maintaining confidence in the marketplace. Health Canada remains committed to reducing unnecessary burden and improving processes while upholding safety.

Thank you, Mr. Chair.

The Chair Liberal Sukh Dhaliwal

Thank you very much. That was perfect timing.

Honourable members, when you ask questions, please identify whether your question is for Ms. Godard or Ms. O'Connor. It would be appreciated. If you feel that the witnesses are going too long, please raise your hand so that I can ask the witnesses to stop immediately. I don't want to interrupt because of the interpreters.

If you can, maintain eye contact with the honourable member who is asking the question.

With that, we will go to Dr. Strauss for five minutes.

Please go ahead.

5:15 p.m.

Conservative

Matt Strauss Conservative Kitchener South—Hespeler, ON

Thank you, Chair.

Ms. Godard, thank you for your presentation. I took from it that your understanding is that these regulations and Vanessa's Law, these changes from 2023, are not terribly burdensome.

I've never owned a business. I've never owned a manufacturing plant. I've never applied for an NHP licence. I don't understand how that can be if so many industry folks, small business owners, people who own shops.... As my colleague Mr. Calkins has explained, the outcry has been immense. I've had entrepreneurs and business owners in my office saying, “We cannot survive these changes. We cannot survive the uncertainty that these changes have caused.” Sadly, and I hate to say it, I have had people in my office tell me, “We are going to move our business to the United States because of these changes.”

I'm just trying to square your general understanding that this is not burdensome with the overwhelming negative feedback that I've been receiving from the community.

5:15 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

The tools introduced in Vanessa's Law shouldn't really add any burden to a company that is compliant or a company that will work with Health Canada if a risk is identified. The authorities that are introduced in Vanessa's Law speak to postmarket authorities—for example, the mandatory recall—that the minister could need if a serious risk to health were to be identified. In that sense, there is no additional burden.

Matt Strauss Conservative Kitchener South—Hespeler, ON

I guess this is still not answering the inconsistency I'm seeing between your testimony and the industry outcry. They've been to the Hill many times. They've booked all these meetings. They've used their time and they've spent money on lobbyists. The disconnect is very palpable, and I'm really having trouble wrapping my mind around it.

One thing that they have told me when they've come and met with me in my office on Hill days related to an interest I have as a lifetime gym-goer in things like protein and creatine. They've explained to me that if they had an idea for a new creatine supplement, they would have to go through these burdensome regulations, but I could order the same product from Amazon and Health Canada would have no oversight over that.

Is that the case?

5:20 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

I'll start, and then I'll turn to my colleagues here on personal importation.

It is true that if you want to market a natural health product in Canada, there is a premarket approval, but those requirements have nothing to do with Vanessa's Law. They're quite separate.

The premarket approval in Canada allows a company to have an NPN and have a health claim that's been substantiated by Health Canada. In terms of how that compares to the U.S. model, in the U.S. a company doesn't need the premarket approval, but they have to put disclaimers on the product indicating that it has not been reviewed by the U.S. FDA and—I'm paraphrasing here—that it can't cure or similarly affect.

Sara O'Connor Director General, Health Product Compliance Directorate, Department of Health

With regard to the personal importation part of your question, yes, Canadians can bring in products from outside Canada.

5:20 p.m.

Conservative

Matt Strauss Conservative Kitchener South—Hespeler, ON

That's fine. That's all I needed to hear to confirm, but this just seems tragic in a time of a trade war. We're trying to buy Canadian and support Canadian industries, and I have all these entrepreneurs coming into my office and having to hire lobbyists to come and tell me about how we're chasing them out of the country. Then that same entrepreneur, once chased out into the United States, can sell me their product on Amazon. If that's the ultimate outcome of the 2023 changes, that's just a crying shame. I hope the members opposite will take that into account.

Here's one, I guess, factoid.

I'm a physician. I specialize in critical care and internal medicine. I would say that two or three times a week throughout my career, I would admit someone to the hospital, sometimes with a deathly illness caused by an adverse reaction to a pharmaceutical product, but I can't think of one time in my career when I've had someone come in with a deadly or near-fatal reaction to a natural health product.

My colleague Dr. Eyolfson spoke about St. John's wort. I've personally admitted hundreds of SSRI overdoses to the hospital. I've not ever seen one hospital admission from St. John's wort in my life, nor have I heard of one from my colleagues.

Would you agree that this is a different class of risk, empirically, and therefore should have a different class or a different intensity of regulation?

5:20 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

There's no doubt about it: Natural health products are lower-risk products. They are not without risk.

The Chair Liberal Sukh Dhaliwal

Thank you. The time is up, Dr. Strauss.

We'll go to Dr. Jaczek for five minutes.

Please go ahead.

Helena Jaczek Liberal Markham—Stouffville, ON

Thank you so much, Chair.

For the committee, could you please explain, Ms. Godard, the difference between a stop sale and a recall, and why a recall, in this particular instance, is important to protect the safety of Canadians?

5:20 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Thank you for the question. I'll turn to my colleague Sara on this one.

5:20 p.m.

Director General, Health Product Compliance Directorate, Department of Health

Sara O'Connor

The difference is that a stop sale could occur at any time and could occur at the manufacturer during an inspection, but a recall is needed when that product has left the manufacturer and may be on retail shelves or in the home of a Canadian. That's when we would have to work with the company to do a recall. It's if the product has reached distribution to Canadians.

Helena Jaczek Liberal Markham—Stouffville, ON

I'm not sure if this is your area of expertise, but with regard to food in grocery stores, I believe it is quite possible that if a product is found to be contaminated, public health can go in and actually, physically, recall the product.

I see Ms. Godard nodding to that. Thank you.

Now, about labelling, if Health Canada identifies a serious new risk that requires an urgent warning on the label, should it be able to require that label change?

5:25 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Indeed. If there is a serious risk to health, there is a need to communicate that risk to Canadians. The label is part of that message to the person using the product.

Helena Jaczek Liberal Markham—Stouffville, ON

Under Bill C-224, what happens if the company refuses to make that change voluntarily?

5:25 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

It's an interesting question, because the authorities in Bill C-224, for example, the label change, allow us to be a bit more flexible. If a company refused, for example, a label change, we would need to look at the various options that we have. I'll turn to my colleague Sara in a minute, but it could mean suspending a licence. It could mean something very much more severe.

Sara, do you have anything to add?

5:25 p.m.

Director General, Health Product Compliance Directorate, Department of Health

Sara O'Connor

It is quite common that we would work with the compliance industry to allow for label changes, not to the product that's on the market maybe, but in a span of time that is reasonable. If there was a need for an immediate label change, those powers could be used to recall the product and then potentially change the label or whatnot. In general, we work with the companies over a reasonable amount of time if there are label changes needed.

Helena Jaczek Liberal Markham—Stouffville, ON

We've heard quite a bit about excessive red tape. In our first session on Monday, Ms. Kramchynsky from Food, Health & Consumer Products of Canada said that she was involved in your consultation regarding reducing red tape. I think that's a worthy goal.

Could you describe a little bit more exactly what's happening with that process and who you're involving, stakeholders, etc.?

5:25 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

We are really trying to find the balance between the burden and ensuring that the products are safe. We are looking at four different projects to reduce the burden on industry. One of them looks to introduce a simple registration process for natural health products. The other one looks to streamline premarket requirements where postmarket oversight is more appropriate. Those two combined would take a premarket scheme that has a service standard of 60 days and requires a certain amount of information, to something that is less burdensome in terms of the amount of information and much more streamlined in how you get the approval so that you can get your product to market faster.

We're also looking to introduce flexible risk-based postmarket vigilance requirements for all NHPs. We were talking about ADRs earlier on. Right now, the requirements are quite rigid. They need yearly summaries. We're taking a more flexible approach looking into that to see if, when something happens and you let us know, we could monitor that way.

Then finally, we're looking to introduce more flexible labelling requirements. I think I heard earlier that sometimes they're small bottles and it's hard to see the labels. We're recognizing that, and we're looking at the digital space as to how we can improve labels, not only for the manufacturer but for the consumer at the other end.

Helena Jaczek Liberal Markham—Stouffville, ON

Do I have time?

The Chair Liberal Sukh Dhaliwal

You have nine seconds. I'd like to thank you.

Now we'll go to Madame Gaudreau for five minutes.

Please go ahead.

Marie-Hélène Gaudreau Bloc Laurentides—Labelle, QC

Thank you, Mr. Chair.

As I said initially, I'm new to this committee, so I wasn't here during the discussions on Vanessa's law, which you mentioned, Ms. Godard. The amendments that were made in 2023 broadened the provisions relating to prevention but also post-market monitoring. That's my understanding.

It's 2026 now.

In the last Parliament, a recommendation was made to provide flexibility. The members agreed but were adamant that the minister's ultimate power to order a recall not be taken away.

Here's my question. How will the bill, as it currently stands, affect the powers or latitude of Health Canada, indeed the minister? In other words, how will it affect what they can do?

5:30 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

That's a very good question.

Passing the bill in its current form would mean that the minister did not have the necessary tools to act quickly when a serious health risk was identified. I'll give you two tools.

Ordering a mandatory recall is one of those tools. When we order a mandatory recall, it means that we have already asked the party concerned to recall the product voluntarily, so this is really a measure of last resort. However, it's an important one. We need a way to act when we don't get the necessary level of co‑operation.

Seeking an injunction is the other post-market tool that can be used. If someone is asked to stop selling a product and simply disregards the request, we can turn to the courts, which have additional tools to really manage the risk.

That's more on the operational side.

The other distinction when it comes to the bill is that, within the regulations, there are flexible regulatory tools. Those are necessary to support our efforts to modernize processes and reduce the burden on industry, which I mentioned earlier. Without those tools, we won't be able to do our work quickly, and that would be unfortunate for the industry.